← Issue №18/ week of Nov 1, 2026/ the whole section, in full

Pancreas/Biliary, in full.

All 6 Pancreas/Biliary papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 6, in full

most clinically useful first
Pancreas/Biliary rct · n=146 · Oct 27, 2026 · Hepatology · IF 18.0

A pivotal Phase 2 study of derazantinib for previously-treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 aberrations: FIDES-01.

New evidencecholangiocarcinomabiomarker
Clinical takeawayOpen-label and non-controlled: activity was concentrated in FGFR2 fusions and modest with mutations or amplifications, and derazantinib was not compared with any other therapy.
What it foundWith FGFR2 fusions (n=103), objective response was 22.3%, median PFS 8.1 months and OS 17.2 months; with FGFR2 mutations or amplifications, response was 9.3%, 3-month PFS 63% and OS 11.9 months. Hyperphosphataemia occurred in 38% and dry eye in 36%, with no grade 4 or 5 drug-related events.
ContextPhase 2 evidence with central radiology review in advanced intrahepatic cholangiocarcinoma after at least one line of chemotherapy.
Emergingsuggested applicable standard· NCCN Biliary Tract Cancers V2.2025 (V1.2026 in circulation) / AASLD 2023 Practice Guidance on PSC and Cholangiocarcinoma

Decision at stakeidentifying actionable targets for later-line therapy in unresectable/metastatic cholangiocarcinoma

… For unresectable or metastatic disease, first-line systemic therapy is gemcitabine plus cisplatin combined with a PD-L1/PD-1 checkpoint inhibitor, either durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966), both listed as category 1 preferred options by NCCN; comprehensive molecular/genomic profiling is recommended for all unresectable/metastatic candidates for systemic therapy to identify actionable targets (e.g., FGFR2 fusions, IDH1 mutations, HER2 amplification) for later-line therapy. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Stage cholangiocarcinoma with multiphasic MRI/MRCP plus CT chest/abdomen/pelvis, obtain tissue via ERCP brush cytology with FISH, cholangioscopy-directed biopsy, or EUS-FNA (avoiding primary perihilar tumor sampling if liver transplant is being considered due to theoretical seeding risk), and manage through a multidisciplinary tumor board with treatment stratified by tumor location: resect (anatomic hepatectomy for intrahepatic, hemihepatectomy with bile duct resection for perihilar, Whipple for distal) with adjuvant capecitabine (category 1, per BILCAP) when resectable. For unresectable or metastatic disease, first-line systemic therapy is gemcitabine plus cisplatin combined with a PD-L1/PD-1 checkpoint inhibitor, either durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966), both listed as category 1 preferred options by NCCN; comprehensive molecular/genomic profiling is recommended for all unresectable/metastatic candidates for systemic therapy to identify actionable targets (e.g., FGFR2 fusions, IDH1 mutations, HER2 amplification) for later-line therapy. Selected unresectable early-stage perihilar tumors may undergo neoadjuvant chemoradiation and liver transplant per the Mayo Clinic protocol at experienced centers, and jaundice or cholangitis is managed with biliary drainage (ERCP preferred over PTC).

NCCN Biliary Tract Cancers V2.2025 (V1.2026 in circulation) / AASLD 2023 Practice Guidance on PSC and Cholangiocarcinoma · reviewed 2026-07-21 ↗
Borad MJ … Mazzaferro V · Hepatology · IF 18.0 · PubMed ↗Permalink
Pancreas/Biliary retrospective · n=984 · Nov 1, 2026 · Liver International · IF 6.7

Screening for Biliary Dysplasia Using Brush Cytology in PSC: Prevalence, Risk Factors and Outcomes.

New evidencecholangiocarcinomabiliary strictureERCPbiomarker
Clinical takeawayIn this 984-patient ERC cohort a negative brush was reassuring, but reported sensitivity of brush cytology varies widely (8% to 89%); the combined ERC-IgG4 score is a proposed tool for tailoring surveillance that the authors say may help.
What it foundBrush cytology had a negative predictive value of 0.99 for excluding cholangiocarcinoma in PSC patients.
ContextCurrent guidelines recommend annual surveillance via ultrasound or MRI/MRCP for PSC, but brush cytology offers a high negative predictive value (0.99) for excluding CCA, potentially refining surveillance strategies in select cases.
Emergingsuggested applicable standard· AASLD 2023 (Bowlus et al., Hepatology 77:659-702) practice guidance on PSC and cholangiocarcinoma, supersedes AASLD 2010; alongside EASL 2022 sclerosing cholangitis guideline

Diagnose PSC with high-quality MRCP as the reference-standard imaging (avoid ERCP for diagnostic purposes; if MRCP findings are equivocal, repeat MRCP rather than proceeding to ERCP), reserving ERCP for therapeutic intervention, and exclude secondary sclerosing cholangitis/IgG4-related disease. … Perform annual abdominal MRI/MRCP with or without serum CA19-9 for cholangiocarcinoma/gallbladder-cancer surveillance in adults with large-duct PSC (not recommended under age 18 or in small-duct PSC). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnose PSC with high-quality MRCP as the reference-standard imaging (avoid ERCP for diagnostic purposes; if MRCP findings are equivocal, repeat MRCP rather than proceeding to ERCP), reserving ERCP for therapeutic intervention, and exclude secondary sclerosing cholangitis/IgG4-related disease. No disease-modifying therapy is proven to alter transplant-free survival, but moderate-dose UDCA (13-23 mg/kg/day) may now be considered and continued in patients not enrolled in or eligible for a clinical trial if it produces a meaningful improvement in alkaline phosphatase (GGT in children) and/or symptoms by 12 months, discontinuing if no response; high-dose UDCA remains contraindicated. Perform annual abdominal MRI/MRCP with or without serum CA19-9 for cholangiocarcinoma/gallbladder-cancer surveillance in adults with large-duct PSC (not recommended under age 18 or in small-duct PSC). Manage gallbladder polyps by size, cholecystectomy for polyps >8 mm, ultrasound surveillance every 6 months for polyps ≤8 mm, rather than referring every polyp. For colorectal surveillance, begin surveillance colonoscopy at the time of PSC-IBD diagnosis (or at age 15 for childhood-onset disease) and repeat at 1-2 year intervals; in PSC without IBD, perform a diagnostic colonoscopy at PSC diagnosis and repeat every 5 years if IBD is not found. Evaluate dominant strictures with brush cytology plus FISH (± cholangioscopy) before/at balloon dilation, repeating ERCP with sampling in 3 months if cytology is suspicious regardless of FISH result. Treat recurrent cholangitis and cholestatic pruritus, maintain bone health, and refer for transplant evaluation for decompensation, intractable pruritus, recurrent bacterial cholangitis, or early-stage CCA per Mayo protocol.

AASLD 2023 (Bowlus et al., Hepatology 77:659-702) practice guidance on PSC and cholangiocarcinoma, supersedes AASLD 2010; alongside EASL 2022 sclerosing cholangitis guideline · reviewed 2026-07-24 ↗
Färkkilä M … Arola J · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
Pancreas/Biliary prospective cohort · n=150 · Oct 27, 2026 · Eur J Gastro Hep · IF 2.2

Impact of restrictive fluid resuscitation strategy on early intestinal epithelial injury markers and inflammatory cytokine levels in patients with acute pancreatitis.

New evidenceacute pancreatitisbiomarkerbasic sciencetranslational
Clinical takeawayConsider using restrictive fluid resuscitation (10 ml/kg bolus only for hypovolemia plus 1.5 ml/kg/h maintenance) in acute pancreatitis patients to reduce intestinal injury markers and systemic inflammation, while minimizing fluid overload.
What it foundRestrictive fluid resuscitation (RFR) reduced D-lactate, intestinal fatty acid-binding protein, and intra-abdominal pressure at 48h, and lowered TNF-alpha and IL-6 at 48h and 72h, compared to conventional fluid resuscitation (CFR). No significant differences were seen in major organ complications or 30-day mortality.
ContextThis study supports a shift from conventional fluid resuscitation (15 ml/kg bolus plus 2.5-3.0 ml/kg/h) to a more restrictive approach, aligning with emerging evidence favoring cautious fluid management in acute pancreatitis patients.
Reinforcessuggested applicable standard· American College of Gastroenterology, "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis" (Tenner S, Vege SS, Sheth SG, et al.), Am J Gastroenterol 2024;119(3):419-437

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Diagnose acute pancreatitis (AP) by the Atlanta criteria (2 of 3: characteristic epigastric/LUQ pain, lipase or amylase >3x ULN [lipase preferred for specificity/duration], or characteristic imaging). ACG 2024 stratifies severity risk using SIRS on admission plus bedside risk factors, rising/elevated BUN, rising/elevated hematocrit (>44), obesity (BMI>30), extrapancreatic fluid collections/pleural effusion/infiltrates, altered mental status, and older age/comorbidities, rather than mandating a formal BISAP or APACHE II composite score. Give moderately aggressive lactated Ringer's, most important in the first 6-12 hours, reassessing volume status/BUN/HCT at 6 hours (further aggressive hydration has little added benefit after 24-48h). Start oral low-fat solid food within 24-48h as tolerated in mild disease; if enteral feeding is needed for moderately severe/severe disease, prefer nasogastric over nasojejunal with small-peptide/medium-chain-triglyceride formula and continuous (not bolus/cyclic) feeding; avoid parenteral nutrition if possible. Do not give prophylactic antibiotics, even in severe disease or sterile necrosis; reserve antibiotics for suspected infected necrosis (typically arising 10-14 days in), and choose agents that penetrate pancreatic necrosis while together covering both gut-derived gram-negative enterics and anaerobes, a carbapenem supplies this as monotherapy, whereas a fluoroquinolone or a third-or-higher-generation cephalosporin must be combined with metronidazole; metronidazole alone (anaerobic cover only), or a cephalosporin or a quinolone alone, does not adequately treat infected necrosis. Perform cholecystectomy preferably before discharge for mild acute biliary pancreatitis, and after a second unexplained AP episode even without identified gallstones; reserve ERCP within 24h for AP complicated by cholangitis, with rectal indomethacin +/- pancreatic duct stent and periprocedural hydration to reduce post-ERCP pancreatitis risk. Check triglycerides when gallstones/alcohol are absent (>1000 mg/dL supports a hypertriglyceridemia etiology). For stable pancreatic necrosis, defer surgical, radiological, or endoscopic intervention 4-6 weeks to allow walling-off (step-up approach).

American College of Gastroenterology, "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis" (Tenner S, Vege SS, Sheth SG, et al.), Am J Gastroenterol 2024;119(3):419-437 · reviewed 2026-07-20 ↗
Huang A, Liang Y · European Journal of Gastroenterology & Hepatology · IF 2.2 · PubMed ↗Permalink
Pancreas/Biliary retrospective · n=173 · Oct 28, 2026 · Pancreatology · IF 3.0

Computed tomography-based embryologic compartment classification provides prognostic stratification in pancreatic head ductal adenocarcinoma.

New evidencepancreatic cancerartificial intelligenceepidemiology
Clinical takeawayA retrospective prognostic classification in 173 resected patients; it was not tested against resectability or treatment decisions and needs validation.
What it foundDorsal-confined (DC) pancreatic head PDAC had a median overall survival of 61.5 months vs 25.2 months in non-DC tumors (HR 0.546, 95% CI 0.323-0.920), based on preoperative contrast-enhanced CT classification into DC, dorsal-predominant (DP), ventral-predominant (VP), and ventral-confined (VC) tumors.
ContextRefines preoperative risk stratification by introducing embryologic compartment classification, which complements existing staging systems, based on a retrospective analysis of 173 patients.
Emergingsuggested applicable standard· National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Pancreatic Adenocarcinoma, Version 2.2025, verified directly against the metastatic first-line algorithm (PANC-10) and Principles of Systemic Therapy (PANC-F, 6 of 13), footnote y: "Good PS is defined as ECOG 0-1 ... and intermediate PS is defined as ECOG 2"; peer-reviewed publication of this guideline series with a resolving identifier: Tempero MA, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19(4):439-457.

… RESECTABLE disease: upfront resection (pancreaticoduodenectomy for head/uncinate; distal pancreatectomy ± splenectomy for body/tail) followed by adjuvant therapy, or neoadjuvant therapy in selected high-risk patients; preferred adjuvant regimen is modified FOLFIRINOX in patients able to tolerate it, ideally begun within 12 weeks of surgery, for a total of ~6 months of perioperative systemic therapy. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Evaluate suspected pancreatic adenocarcinoma with a dedicated pancreatic-protocol (multiphasic, contrast-enhanced) CT of the abdomen as the preferred imaging for diagnosis and staging (MRI/MRCP is an acceptable alternative); PET/CT may be added after, never as a substitute for, protocol CT/MRI in higher-risk situations. Obtain tissue confirmation, preferably by EUS-guided FNA/FNB with core biopsy where feasible; biopsy is generally required before neoadjuvant or palliative therapy, whereas patients with clearly resectable disease may proceed to surgery without preoperative biopsy. Measure baseline CA 19-9 (interpret after biliary decompression / with normal bilirubin; it can be falsely low in Lewis-antigen-negative patients and falsely elevated with cholestasis). Offer GERMLINE testing for inherited susceptibility to EVERY patient with confirmed pancreatic adenocarcinoma regardless of family history, using a comprehensive multi-gene panel; separately, for patients with locally advanced or metastatic disease who are candidates for anti-cancer therapy, obtain TUMOR/SOMATIC molecular profiling (broad NGS; RNA-based assays improve fusion detection; cell-free/liquid biopsy if tissue is insufficient). Assign resectability, resectable, borderline resectable, locally advanced (unresectable), or metastatic, by multidisciplinary review, ideally at a high-volume center. RESECTABLE disease: upfront resection (pancreaticoduodenectomy for head/uncinate; distal pancreatectomy ± splenectomy for body/tail) followed by adjuvant therapy, or neoadjuvant therapy in selected high-risk patients; preferred adjuvant regimen is modified FOLFIRINOX in patients able to tolerate it, ideally begun within 12 weeks of surgery, for a total of ~6 months of perioperative systemic therapy. BORDERLINE RESECTABLE and LOCALLY ADVANCED disease: neoadjuvant systemic therapy, with or without subsequent chemoradiation/RT, then restaging and reassessment for resection. METASTATIC disease by performance status: good PS (ECOG 0-1, adequate organ function), first-line FOLFIRINOX/modified FOLFIRINOX, NALIRIFOX, or gemcitabine + nab-paclitaxel, with clinical trial preferred; after ~4-6 months without progression, transition to a maintenance strategy (including olaparib for germline BRCA1/2 carriers who have NOT progressed on first-line platinum-based therapy), a clinical trial, or a treatment break; intermediate PS (ECOG 2), clinical trial preferred, otherwise less-intensive first-line therapy (preferred gemcitabine + nab-paclitaxel [category 1], or single-agent gemcitabine or capecitabine, or FOLFOX/FOLFIRI/CapeOx), since the intensive triplets (FOLFIRINOX/modified FOLFIRINOX and NALIRIFOX) are limited to ECOG 0-1 and are generally not appropriate at ECOG 2, with the same maintenance-versus-progression reassessment applied after ~4-6 months without progression; poor PS (ECOG 3-4), palliative/best supportive care, with single-agent chemotherapy or a biomarker-directed agent only if clinically appropriate. Treat by molecular target wherever an actionable alteration is present, across lines: pembrolizumab (or dostarlimab) for MSI-H/dMMR and pembrolizumab for TMB-H, olaparib for germline BRCA1/2 (maintenance after platinum), larotrectinib/entrectinib for NTRK fusions, selpercatinib for RET fusions, dabrafenib + trametinib for BRAF V600E, erdafitinib for FGFR2 alterations, fam-trastuzumab deruxtecan for HER2-positive disease, zenocutuzumab for NRG1 fusion-positive disease, and (in recent NCCN versions) KRAS G12C inhibitors (adagrasib/sotorasib), several of these after prior systemic therapy. Integrate supportive care throughout: relieve obstructive jaundice with an endoscopic self-expanding metal stent in non-operative or neoadjuvant pathways, but do NOT perform routine preoperative biliary drainage before planned upfront resection; treat exocrine insufficiency with pancreatic enzyme replacement titrated to symptoms (common starting dose ~40,000-50,000 units of lipase with main meals, roughly half with snacks, increased as needed); manage refractory pain with celiac plexus neurolysis or palliative RT; relieve gastric outlet obstruction with surgical or EUS-guided gastrojejunostomy (or enteral stenting); and provide VTE prophylaxis, nutritional support, and early palliative care.

National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Pancreatic Adenocarcinoma, Version 2.2025, verified directly against the metastatic first-line algorithm (PANC-10) and Principles of Systemic Therapy (PANC-F, 6 of 13), footnote y: "Good PS is defined as ECOG 0-1 ... and intermediate PS is defined as ECOG 2"; peer-reviewed publication of this guideline series with a resolving identifier: Tempero MA, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19(4):439-457. · reviewed 2026-07-23 ↗
Kozono S … Nakano T · Pancreatology : Official Journal of the International Association of Pancreatology (IAP) .. [et Al.] · IF 3.0 · PubMed ↗Permalink
Pancreas/Biliary review · Oct 26, 2026 · Pancreatology · IF 3.0

IgG4-related autoimmune pancreatitis: a journey.

New therapyautoimmune pancreatitisbiomarkertranslationalbasic science
Clinical takeawayNo clinical action from this historical review: it reports no trial results and does not compare CD19-targeted agents with corticosteroids.
What it foundThe review traces IgG4-related disease and type 1 autoimmune pancreatitis from early case descriptions through the 2011 international consensus criteria to CD19-targeted agents tested in the MITIGATE and INDIGO trials, and discusses FAPI-PET and cancer risk.
ContextThis review highlights the evolution of IgG4-RD treatment from corticosteroids to targeted therapies, aligning with current practice trends.
Emergingsuggested applicable standard· American College of Gastroenterology, 'ACG Clinical Guideline: Chronic Pancreatitis' (Gardner TB et al., Am J Gastroenterol 2020;115(3):322-339). DOI 10.14309/ajg.0000000000000535, PMID 32022720.

… Screen for PDAC per lifetime risk and pursue etiologic workup via TIGAR-O v2, including genetic testing and autoimmune pancreatitis evaluation.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Confirm chronic pancreatitis on CROSS-SECTIONAL IMAGING, CT for late calcific disease, MRI/MRCP (with secretin where available) for earlier ductal and parenchymal change, EUS an acceptable alternative; per ACG 2020, "Diagnosis is made usually on cross-sectional imaging, with modalities such as endoscopic ultrasonography and pancreatic function tests playing a secondary role". Fecal elastase does NOT confirm chronic pancreatitis: it is a test of exocrine FUNCTION and is the appropriate initial test for the exocrine pancreatic insufficiency (EPI) that chronic pancreatitis causes, a consequence of the disease, not the diagnosis of it. A normal fecal elastase does not exclude chronic pancreatitis and a low one does not establish it. Per AGA 2023, fecal elastase must be run on a semi-solid or solid stool specimen; below 100 mcg/g is good evidence of EPI and 100-200 mcg/g is indeterminate (below 200 mcg/g is the cutoff commonly used to screen). Then manage with smoking and alcohol cessation, PERT for exocrine insufficiency titrated to symptoms, fat-soluble vitamin and bone surveillance, and individualized type 3c diabetes control, considering insulin early in patients with marked hyperglycemia or symptoms of insulin deficiency. Treat pain with a stepwise ladder from scheduled acetaminophen and neuromodulators to EUS-guided celiac plexus block and endoscopic/surgical intervention, referring early for surgery per ESCAPE 2020 in candidates with main pancreatic duct obstruction. Screen for PDAC per lifetime risk and pursue etiologic workup via TIGAR-O v2, including genetic testing and autoimmune pancreatitis evaluation.

American College of Gastroenterology, 'ACG Clinical Guideline: Chronic Pancreatitis' (Gardner TB et al., Am J Gastroenterol 2020;115(3):322-339). DOI 10.14309/ajg.0000000000000535, PMID 32022720. · reviewed 2026-07-21 ↗
Löhr JM · Pancreatology : Official Journal of the International Association of Pancreatology (IAP) .. [et Al.] · IF 3.0 · PubMed ↗Permalink
Pancreas/Biliary prospective cohort · Oct 26, 2026 · Pancreatology · IF 3.0

UBE2T-driven lipid metabolic reprogramming links chronic inflammation to pancreatic cancer progression.

Basic sciencebasic sciencetranslationalpancreatic cancer
Clinical takeawayNo clinical action yet: a mechanistic finding in mice showing UBE2T as a potential therapeutic target for PDAC.
What it foundUBE2T depletion and PGG treatment reduced pancreatic lesion burden and lipid accumulation in mouse models of PDAC.
ContextThis study identifies UBE2T as a molecular link between chronic inflammation and lipid metabolic reprogramming in PDAC, a novel mechanistic insight.
Emergingsuggested applicable standard· National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Pancreatic Adenocarcinoma, Version 2.2025, verified directly against the metastatic first-line algorithm (PANC-10) and Principles of Systemic Therapy (PANC-F, 6 of 13), footnote y: "Good PS is defined as ECOG 0-1 ... and intermediate PS is defined as ECOG 2"; peer-reviewed publication of this guideline series with a resolving identifier: Tempero MA, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19(4):439-457.

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Evaluate suspected pancreatic adenocarcinoma with a dedicated pancreatic-protocol (multiphasic, contrast-enhanced) CT of the abdomen as the preferred imaging for diagnosis and staging (MRI/MRCP is an acceptable alternative); PET/CT may be added after, never as a substitute for, protocol CT/MRI in higher-risk situations. Obtain tissue confirmation, preferably by EUS-guided FNA/FNB with core biopsy where feasible; biopsy is generally required before neoadjuvant or palliative therapy, whereas patients with clearly resectable disease may proceed to surgery without preoperative biopsy. Measure baseline CA 19-9 (interpret after biliary decompression / with normal bilirubin; it can be falsely low in Lewis-antigen-negative patients and falsely elevated with cholestasis). Offer GERMLINE testing for inherited susceptibility to EVERY patient with confirmed pancreatic adenocarcinoma regardless of family history, using a comprehensive multi-gene panel; separately, for patients with locally advanced or metastatic disease who are candidates for anti-cancer therapy, obtain TUMOR/SOMATIC molecular profiling (broad NGS; RNA-based assays improve fusion detection; cell-free/liquid biopsy if tissue is insufficient). Assign resectability, resectable, borderline resectable, locally advanced (unresectable), or metastatic, by multidisciplinary review, ideally at a high-volume center. RESECTABLE disease: upfront resection (pancreaticoduodenectomy for head/uncinate; distal pancreatectomy ± splenectomy for body/tail) followed by adjuvant therapy, or neoadjuvant therapy in selected high-risk patients; preferred adjuvant regimen is modified FOLFIRINOX in patients able to tolerate it, ideally begun within 12 weeks of surgery, for a total of ~6 months of perioperative systemic therapy. BORDERLINE RESECTABLE and LOCALLY ADVANCED disease: neoadjuvant systemic therapy, with or without subsequent chemoradiation/RT, then restaging and reassessment for resection. METASTATIC disease by performance status: good PS (ECOG 0-1, adequate organ function), first-line FOLFIRINOX/modified FOLFIRINOX, NALIRIFOX, or gemcitabine + nab-paclitaxel, with clinical trial preferred; after ~4-6 months without progression, transition to a maintenance strategy (including olaparib for germline BRCA1/2 carriers who have NOT progressed on first-line platinum-based therapy), a clinical trial, or a treatment break; intermediate PS (ECOG 2), clinical trial preferred, otherwise less-intensive first-line therapy (preferred gemcitabine + nab-paclitaxel [category 1], or single-agent gemcitabine or capecitabine, or FOLFOX/FOLFIRI/CapeOx), since the intensive triplets (FOLFIRINOX/modified FOLFIRINOX and NALIRIFOX) are limited to ECOG 0-1 and are generally not appropriate at ECOG 2, with the same maintenance-versus-progression reassessment applied after ~4-6 months without progression; poor PS (ECOG 3-4), palliative/best supportive care, with single-agent chemotherapy or a biomarker-directed agent only if clinically appropriate. Treat by molecular target wherever an actionable alteration is present, across lines: pembrolizumab (or dostarlimab) for MSI-H/dMMR and pembrolizumab for TMB-H, olaparib for germline BRCA1/2 (maintenance after platinum), larotrectinib/entrectinib for NTRK fusions, selpercatinib for RET fusions, dabrafenib + trametinib for BRAF V600E, erdafitinib for FGFR2 alterations, fam-trastuzumab deruxtecan for HER2-positive disease, zenocutuzumab for NRG1 fusion-positive disease, and (in recent NCCN versions) KRAS G12C inhibitors (adagrasib/sotorasib), several of these after prior systemic therapy. Integrate supportive care throughout: relieve obstructive jaundice with an endoscopic self-expanding metal stent in non-operative or neoadjuvant pathways, but do NOT perform routine preoperative biliary drainage before planned upfront resection; treat exocrine insufficiency with pancreatic enzyme replacement titrated to symptoms (common starting dose ~40,000-50,000 units of lipase with main meals, roughly half with snacks, increased as needed); manage refractory pain with celiac plexus neurolysis or palliative RT; relieve gastric outlet obstruction with surgical or EUS-guided gastrojejunostomy (or enteral stenting); and provide VTE prophylaxis, nutritional support, and early palliative care.

National Comprehensive Cancer Network (NCCN), NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Pancreatic Adenocarcinoma, Version 2.2025, verified directly against the metastatic first-line algorithm (PANC-10) and Principles of Systemic Therapy (PANC-F, 6 of 13), footnote y: "Good PS is defined as ECOG 0-1 ... and intermediate PS is defined as ECOG 2"; peer-reviewed publication of this guideline series with a resolving identifier: Tempero MA, et al. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19(4):439-457. · reviewed 2026-07-23 ↗
Xiao L … Jiao Z · Pancreatology : Official Journal of the International Association of Pancreatology (IAP) .. [et Al.] · IF 3.0 · PubMed ↗Permalink
← Back to issue №18 Every section of this issue is one click away, at the top of this page. Follow Pancreas/Biliary by RSS